Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 8, 2005, Pages 3529-3532

  Pultz, Nicole J ^a   Donskey, Curtis J ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ANAEROBIC BACTERIUM; ANIMAL EXPERIMENT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; FEMALE; INTESTINE FLORA; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXIN SYNTHESIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BACTERIAL TOXINS; CECUM; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; FEMALE; HUMANS; MICE;

EID: 23044492161     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.8.3529-3532.2005     Document Type: Article

References (23)

1. Borriello, S. P., F. E. Barclay, and A. R. Welch. 1988. Evaluation of the predictive capability of an in-vitro model of colonization resistance to Clostridium difficile infection. Microb. Ecol. Health Dis. 1:61-64.
2. Donskey, C. J. 2004. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin. Infect. Dis. 39:219-226.
3. Donskey, C. J., M. S. Helfand, N. J. Pultz, and L. B. Rice. 2004. Effect of parenteral fluoroquinolone administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. Antimicrob. Agents Chemother. 48:326-328.
4. Fekety, R., J. Silva, R. Toshniwal, M. Allo, J. Armstrong, R. Browne, J. Ebright, and G. Rifkin. 1979. Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. Rev. Infect. Dis. 1:386-396.
5. Freeman, J., F. J. O'Neill, and M. H. Wilcox. 2003. Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J. Antimicrob. Chemother. 52:96-102.
6. Gaynes, R., D. Rimland, E. Killum, K. Lowery, T. M. Johnson, G. Kilgore, and F. C. Tenover. 2004. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin. Infect. Dis. 28:640-645.
7. Gerding, D. N. 2004. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: This is an antimicrobial resistance problem. Clin. Infect. Dis. 38:646-648.
8. Golledge, C. L., C. F. Carson, G. L. O'Neill, R. A. Bowman, and T. V. Riley. 1992. Ciprofloxacin and Clostridium difficile-associated diarrhea. J. Antimicrob. Chemother. 30:141-147.
9. Kager, L., B. Brismar, A. S. Malmborg, and C. E. Nord. 1985. Effect of aztreonam on the colon microflora in patients undergoing colorectal surgery. Infection 13:111-114.
10. McCusker, M. E., A. D. Harris, E. Perencevich, and M. C. Roghmann. 2003. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg. Infect. Dis. 9:730-733.
11. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow anaerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. Pultz, N. J., A. Hujer, and C. J. Donskey. 2004. Denaturing gradient gel electrophoresis as a tool to analyze the stool microbiota of laboratory mice, abstr. N-109, p. 136. Abstr. 104th Gen. Meet. Am. Soc. Microbiol. American Society for Microbiology, Washington, D.C.
13. Pultz, N. J., U. Stiefel, M. Ghannoum, M. S. Helfand, and C. J. Donskey. 2005. Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice. Antimicrob. Agents Chemother. 49:438-440.
14. Rolfe, R. D., and S. M. Finegold. 1983. Intestinal β-lactamase activity in ampicillin-induced, Clostridium difficile-associated ileocecitis. J. Infect. Dis. 147:227-235.
15. Settle, C. D., M. H. Wilcox, W. N. Fawley, O. J. Corrado, and P. M. Hawkey. 1998. Prospective study of the risk of Clostridium difficile diarrhea in elderly patients following treatment with cefotaxime or piperacillin- tazobactam. Aliment. Pharmacol. Ther. 12:1217-1223.
16. Stiefel, U., N. J. Pultz, M. S. Helfand, and C. J. Donskey. 2003. Increased susceptibility to vancomycin-resistant Enterococcus intestinal colonization persists after completion of anti-anaerobic antibiotic treatment in mice. Infect. Control Hosp. Epidemiol. 25:373-379.
17. Sullivan, A., C. Edlund, and C. E. Nord. 2001. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect. Dis. 1:101-114.
18. Wilcox, M. H., S. Baines, J. Freeman, S. Qamer, and F. O'Neill. 2003. Piperacillin-tazobactam does not induce Clostridium difficile toxin production in a human gut model, abstr. K-728, p. 366. Program Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C.
19. Wilcox, M. H., J. Freeman, W. Fawley, S. MacKinlay, A. Brown, K. Donaldson, and O. Corrado. 2004. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhea. J. Antimicrob. Chemother. 54:168-172.
20. Wilson, K. H., J. N. Sheagren, and R. Freter. 1985. Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster. J. Infect. Dis. 151:355-361.
21. Wilson, K. H. 1993. The microecology of Clostridium difficile. Clin. Infect. Dis. 16(Suppl. 4):S214-S218.
22. Wistrom, J., S. R. Norrby, E. B. Myhre, S. Eriksson, G. Granstrom, L. Lagergren, G. Englund, C. E. Nord, and B. Svenungsson. 2001. Frequency of antibiotic-associated diarrhea in 2462 antibiotic-treated hospitalized patients: a prospective study. J. Antimicrob. Chemother. 47:43-50.
23. Yip, C., M. Loeb, S. Salama, L. Moss, and J. Olde. 2001. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect. Control Hosp. Epidemiol. 22:572-575.